 Shares of Spero Therapeutics Inc. SPRO, 277.39 soared 188.4 in trading on Thursday morning after the company signed an exclusive license agreement with GlaxoSmithKline GSK, -0.32 for its experimental antibiotic for complicated urinary tract infections. Speros therapy, tebipenem HBr, is expected to enter Phase 3 clinical trials next year. 